Overview

A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1

Status:
Active, not recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in patients with Advanced Primary Hyperoxaluria Type 1 (PH1).
Phase:
Phase 3
Details
Lead Sponsor:
Alnylam Pharmaceuticals